Drugs / licogliflozin
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01915849 | Jul 2013 → Jan 2014 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT01407003 | Jun 2011 → Feb 2013 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 210 trials · 4 met primary · 1 missed | ||||||
| Phase 2 | NCT04065841 | Dec 2019 → Oct 2022 | metabolic dysfunction-associated steatohepatitis | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03320941 | Dec 2017 → Jul 2018 | obesity disorder | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT03205150 | Oct 2017 → Nov 2019 | metabolic dysfunction-associated steatohepatitis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT03152552 | Jul 2017 → Jun 2018 | diabetes mellitus, noninsulin-dependent, 2 | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03152591 | Jul 2017 → Jun 2018 | polycystic ovary syndrome | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT03198767 | Jun → Sep 2017 | obesity disorder | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03100058 | May 2017 → Mar 2018 | obesity disorder | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT03131479 | Apr 2017 → Jan 2018 | impaired renal function disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01824264 | Nov 2015 → Nov 2016 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT02470403 | Jun 2015 → Apr 2016 | morbid obesity | Novartis Pharmaceuticals | Completed | Met primary |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | licogliflozin | “We tested the hypothesis that inhibition of both the sodium-glucose cotransporters 1 and 2 with licogliflozin would lead to improvement in NASH.” PMID 35725922 ↗ Jun 20222“LIK066 (licogliflozin) is a dual sodium glucose co-transporter 1/2 inhibitor with potential benefits in weight loss.” PMID 32072763 ↗ Mar 2020 |
| Known as | Licogliflozina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297625 ↗ |
| Known as | Licogliflozine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297625 ↗ |
| Known as | LIK066 | “Oral Tropifexor (LJN452) & Licogliflozin (LIK066) Combination Therapy” NCT04065841 ↗ |
| Action | Inhibit | “inhibition of both the sodium-glucose cotransporters 1 and 2 with licogliflozin” PMID 35725922 ↗ Jun 20222“Sodium/glucose cotransporter 1 inhibitor” CHEMBL4297625 ↗ “Sodium/glucose cotransporter 2 inhibitor” CHEMBL4297625 ↗ |
| Modality | Small molecule | — CHEMBL4297625 ↗ |
| Route | Oral | “Orally Administered LIK066” NCT01915849 ↗ |
| Target | SLC5A1 | “Sodium/glucose cotransporter 1 inhibitor” CHEMBL4297625 ↗ |
| Target | SLC5A2 | “Sodium/glucose cotransporter 2 inhibitor” CHEMBL4297625 ↗ |